CN104306707A - Medicament composition for treating bedsore - Google Patents
Medicament composition for treating bedsore Download PDFInfo
- Publication number
- CN104306707A CN104306707A CN201410652385.XA CN201410652385A CN104306707A CN 104306707 A CN104306707 A CN 104306707A CN 201410652385 A CN201410652385 A CN 201410652385A CN 104306707 A CN104306707 A CN 104306707A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- rhizoma
- radix
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000004210 Pressure Ulcer Diseases 0.000 title abstract description 10
- 239000000203 mixture Substances 0.000 title abstract description 8
- 239000008280 blood Substances 0.000 claims abstract description 43
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 17
- 239000004863 Frankincense Substances 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 208000025865 Ulcer Diseases 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims description 29
- 231100000397 ulcer Toxicity 0.000 claims description 28
- 241000717739 Boswellia sacra Species 0.000 claims description 12
- 241000959626 Calvatia Species 0.000 claims description 12
- 241000628997 Flos Species 0.000 claims description 12
- 240000005175 Turpinia pomifera Species 0.000 claims description 12
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 12
- 239000002674 ointment Substances 0.000 claims description 8
- 229940040145 liniment Drugs 0.000 claims description 5
- 239000000865 liniment Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- -1 tincture Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 9
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 241000759833 Cornus officinalis Species 0.000 abstract 1
- 241000133231 Marshallia caespitosa Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241001522129 Pinellia Species 0.000 abstract 1
- 235000003417 Plumeria rubra f acutifolia Nutrition 0.000 abstract 1
- 244000040691 Plumeria rubra f. acutifolia Species 0.000 abstract 1
- 244000173853 Sanguisorba officinalis Species 0.000 abstract 1
- 235000008282 Sanguisorba officinalis Nutrition 0.000 abstract 1
- 241001436151 Turpinia arguta Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 14
- 208000027418 Wounds and injury Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 206010040943 Skin Ulcer Diseases 0.000 description 8
- 206010047700 Vomiting Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000007812 deficiency Effects 0.000 description 7
- 230000036407 pain Effects 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 206010007247 Carbuncle Diseases 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 230000002035 prolonged effect Effects 0.000 description 6
- 231100000019 skin ulcer Toxicity 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000008673 vomiting Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010015150 Erythema Diseases 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000010392 Bone Fractures Diseases 0.000 description 4
- 206010063560 Excessive granulation tissue Diseases 0.000 description 4
- 206010017076 Fracture Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 208000010513 Stupor Diseases 0.000 description 4
- 210000001126 granulation tissue Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 206010067171 Regurgitation Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 230000023597 hemostasis Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000035922 thirst Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010054787 Haemorrhoidal haemorrhage Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000002310 elbow joint Anatomy 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001769 paralizing effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000000954 sacrococcygeal region Anatomy 0.000 description 2
- 230000004206 stomach function Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 201000006306 Cor pulmonale Diseases 0.000 description 1
- 206010013789 Dry throat Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 208000018779 Globus Sensation Diseases 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019705 Hepatic pain Diseases 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 206010028748 Nasal obstruction Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000004186 Pulmonary Heart Disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010040007 Sense of oppression Diseases 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010051373 Wound haemorrhage Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/739—Sanguisorba (burnet)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a medicament composition for treating bedsore. The medicament composition comprises the following components: pinellia ternate, puffball, sanguisorba officinalis, frankincense, rhizoma polygonati, coptidis rhizome, white peony root, turpinia arguta seem, herba houttuyniae, radix angelicae, cornus officinalis and pagodatree flower bud. The medicament composition fully plays the effects of managing Qi and activating blood; the effect of treating the bedsore caused by Qi-stagnancy and blood stasis is outstanding and reliable; the preparation technology of the medicament composition is easy to operate, the raw materials are readily available, and adverse reactions are avoided.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of pharmaceutical composition for the treatment of decubital ulcer.
Background technology
Along with Chinese society economy and scientific and technical development, the average life span extends gradually, and the ratio of old people shared by population is increasing.The aging of social population makes spectrum of disease there occurs corresponding change.At present, cardiovascular and cerebrovascular disease, diabetes, tumor, apoplexy etc. have become common frdquently encountered disease, and trauma fracture incidence rate also rises year by year, and the patient that decubital ulcer occurs because these factors cause long-term bed not rise grows with each passing day.
Decubital ulcer has another name called " bed-sore ".Many because of prolonged illness bed, QI-blood circulation is lost smooth, failure of skin and muscle to be nourished, and often because friction skin is broken, contamination forms.Be mainly in the easily pressurized position such as tail sacrum, elbow ankle, ridge, with skin ulceration, the open sore part is prolonged is not more feature.Principal character is skin ulceration, does not prolongedly heal.Be more common in the prolonged illness sickbed patients such as stupor, paralysis, fracture, large-area burns clinically.Be divided into by its clinical characters and systemic conditions: qi stagnation and blood stasis type, accumulate poison rot type, QIXUELIANGXU type.
The traditional Chinese medical science is thought, decubital ulcer is many, and because of reasons such as prolonged illness, severe disease, hemiplegia, stupors, to cause patient confined to bed for a long time, cause patients blood's virtual loss, run and lose freely, failure of skin and muscle to be nourished, limbs of a specified duration seat cotton-padded mattress, fail often to change one's position body so that the long-term pressurized of skin and flesh, local skin becomes fragile, chafing against skin is namely damaged a little, so very easily infect into skin ulcer.Its basic pathogenesis is prolonged illness, the loss of lying on bed for a long time patient healthy energy, deficient qi and blood, and again because of long-term bed, meridians intercept, qi depression to blood stasis, and it is downright bad that local skin accumulates poison, and ulceration becomes skin ulcer.The disease feature of qi stagnation and blood stasis type patients with bedsore is skin rubefaction or purple dark, forms black slough rapidly, occurs limitation table fester, then full thickness skin and subcutaneous, hurt like hell is developed to, companion's susceptible to lose temper due to restlessness, two side of body distensions, bitter taste in the mouth and dry throat, white and thin fur, stringy and rolling pulse.
Because qi stagnation and blood stasis type decubital ulcer disease has a strong impact on the healthy of gerontal patient and quality of life, it often makes the stasis of blood gradually very because of the stagnation of QI, or causes the stagnation of QI because of blood stasis, and venation is obstructed, stagnation of QI and blood may bring about pain.The traditional Chinese medical science is cured the disease exquisite treatment must aim at the pathogenesis of disease, and Chinese medicine is little in treatment qi stagnation and blood stasis type decubital ulcer disease toxic and side effects, curative effect is more definite, is necessary the method studying effective treatment qi stagnation and blood stasis type decubital ulcer disease for this reason.
Summary of the invention
The invention provides a kind of new pharmaceutical composition for the treatment of decubital ulcer, this pharmaceutical composition good effect, toxic and side effects is little, and it is obtained by following raw material: the Rhizoma Pinelliae, Lasiosphaera Seu Calvatia, Radix Sanguisorbae, Olibanum, Rhizoma Polygonati, Rhizoma Coptidis, the Radix Paeoniae Alba, Turpinia pomifera(Roxb) D O., Herba Houttuyniae, the Radix Angelicae Dahuricae, Fructus Corni, the Flos Sophorae Immaturus.
In pharmaceutical composition of the present invention, the described Rhizoma Pinelliae, pungent, temperature; Poisonous.Return spleen, stomach, lung meridian.Drying dampness to eliminate phlegm, stopping nausea and vomiting by lowering the adverse flow of QI, dissolving lump and resolving mass.For abundant expectoration cough with asthma, phlegm retention vertigo and palpitation, dizziness due to wind-phlegm, syncope due to accumulation of phlegm is had a headache, vomiting regurgitation, and breast gastral cavity painful abdominal mass is vexed, globus hystericus; Raw with external treatment carbuncle sucutaneous nodule.Rhizoma Pinelliae (processed with Rhizoma Zingiberis Recens) is used for stopping nausea and vomiting by lowering the adverse flow of QI.
Lasiosphaera Seu Calvatia, pungent, flat.Return lung meridian.Removing heat from the lung and relieving sorethroat, hemostasis.For the strongly fragrant lung pharyngalgia of wind heat, cough, hoarseness; External treatment epistaxis, wound hemorrhage.
Radix Sanguisorbae, bitter, sour, puckery, be slightly cold.Cooling blood for hemostasis, removing toxic substances sore.For having blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, burn due to hot liquid or fire, carbuncle sore tumefacting virus.
Olibanum, pungent, bitter, temperature.Promoting blood circulation and stopping pain.For all pains of trusted subordinate, the contracture of muscle arteries and veins, traumatic injury, sore, carbuncle and painful swelling; Externally used detumescence granulation promoting.
Rhizoma Polygonati, sweet, flat.Return spleen, lung, kidney channel.Boosting qi and nourishing yin, spleen invigorating, lung moistening, kidney tonifying.For weakness of the spleen and stomach, fatigue and asthenia, xerostomia lack of appetite, deficiency of the lung cough caused by dryness, asthenia of essence and blood, interior-heat is quenched one's thirst.
Rhizoma Coptidis, bitter, cold.GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel.Heat clearing and damp drying, eliminating fire and detoxication.For damp and hot feeling of fullness, vomiting acid regurgitation, dysentery, jaundice, unconsciousness due to high fever, hyperactivity of heart-fire, dysphoria and insomnia, heat in blood tells nosebleed, conjunctival congestion, and toothache, quenches one's thirst, carbuncle furuncle; External treatment eczema, eczema, auditory meatus is suppurated.It is burning hot that Rhizoma Coptidis (processed with wine) is apt to the clear part of the body cavity above the diaphragm housing the heart and lungs.For conjunctival congestion, aphtha.Prepared RHIZOMA COPTIDIS with rhizoma zingiberis recens juice clearing stomach stomach function regulating preventing or arresting vomiting.Tie mutually for cold and heat, damp and hot middle resistance, feeling of fullness is vomitted.Cornel Rhizoma Coptidis soothing liver-QI stomach function regulating preventing or arresting vomiting.For incoordination between the liver and stomach, vomiting acid regurgitation.
The Radix Paeoniae Alba, bitter, sour, be slightly cold.Return liver, spleen channel.Suppressing the hyperactive liver pain relieving, nourishing blood for regulating menstruation, astringing YIN to stop sweating.Dizzy for having a headache, hypochondriac pain, stomachache, limb pain twin, blood deficiency and yellow complexion, menoxenia, spontaneous perspiration, night sweat.
Turpinia pomifera(Roxb) D O. is bitter, cold.Promoting blood circulation and stopping pain; Removing toxic substances and promoting subsidence of swelling.Main traumatic injury; Spleen enlargement; Tonsillitis; Furuncle toxic swelling.
Herba Houttuyniae, pungent, be slightly cold.Return lung meridian.Heat-clearing and toxic substances removing, eliminating carbuncle evacuation of pus, inducing diuresis for treating stranguria syndrome.For lung abscess vomiting pus, expectorant dyspnea of heat type is coughed, hematodiarrhoea, pyretic stranguria, carbuncle sore tumefacting virus.
The Radix Angelicae Dahuricae, pungent, temperature.Return stomach, large intestine, lung meridian.Loose wind dehumidifying, understand things pain-stopping, detumescence and apocenosis.For headache due to common cold, supraorbital bone pain, nasal obstruction, nasal sinusitis, toothache, leucorrhea, skin infection swells and ache.
Fructus Corni, sour, puckery, tepor.Return liver, kidney channel.Liver and kidney tonifying, essence astringing and desertion stemming.For vertigo and tinnitus, soreness of waist and knee joint, impotence and seminal emission, enuresis frequent micturition, bleeding not during menses, profuse sweating is collapsed.Interior-heat is quenched one's thirst.
The Flos Sophorae Immaturus, cooling blood for hemostasis, purging liver-fire.For having blood in stool, hemorrhoidal bleeding, dysentery, metrorrhagia, haematemesis, epistaxis, liver-heat conjunctival congestion, have a headache dizzy.
For old patients with bedsore, deficiency in both Qi and blood, qi depression to blood stasis are the basic pathogenesis of old decubital ulcer, and the deficiency of vital energy is this, and blood stasis is mark, and patients with bedsore is because of struggle between vital QI and pathogen, and with the passing of time disease touching, lying on bed for a long time bed, and to healthy energy consume, deficient qi and blood, can not ask heresy to go out.The deficiency of vital energy then can not promoting the circulation of blood, and blood deficiency then gas can not be gone, and the QI and blood deficiency then stasis of blood is stagnant obstructed, and healthy energy does not reach, and directly have influence on local organization reparation slow, the long-term crevasse of wound surface is not healed.The present invention is pure Chinese medicinal preparation, to human body particularly to liver avirulence.Pharmaceutical composition of the present invention follows strengthening vital QI to eliminate pathogenic factors, the Therapeutic Principle for the treatment of both the principal and secondary aspects of a disease, and all medicines share, and plays effect of vital energy regualting and blood circulation-promoting altogether.This method is used for mechanism of qi and blocks and the stagnant person of the blood vessels stasis of blood, reaches the effect for the treatment of both the principal and secondary aspects of a disease at the therapeutic process of decubital ulcer.
The technical scheme adopted for solving its technical problem is the pharmaceutical composition of described treatment decubital ulcer, is made up of the medicine material of following weight: Rhizoma Pinelliae 5-20 part, Lasiosphaera Seu Calvatia 2-9 part, Radix Sanguisorbae 10-18 part, Olibanum 1.2-1.8 part, Rhizoma Polygonati 10-20 part, Rhizoma Coptidis 6-18 part, Radix Paeoniae Alba 2-8 part, Turpinia pomifera(Roxb) D O. 18-30 part, Herba Houttuyniae 10-18 part, Radix Angelicae Dahuricae 15-25 part, Fructus Corni 10-20 part, Flos Sophorae Immaturus 20-26 part.
The preferred technical solution of the present invention is, described pharmaceutical composition of the present invention is obtained by the raw material of following weight portion: the Rhizoma Pinelliae 13 parts, Lasiosphaera Seu Calvatia 5 parts, Radix Sanguisorbae 14 parts, Olibanum 1.5 parts, Rhizoma Polygonati 15 parts, Rhizoma Coptidis 12 parts, the Radix Paeoniae Alba 5 parts, Turpinia pomifera(Roxb) D O. 24 parts, Herba Houttuyniae 14 parts, the Radix Angelicae Dahuricae 20 parts, Fructus Corni 15 parts, the Flos Sophorae Immaturus 23 parts.
Present invention also offers the preparation method of described pharmaceutical composition, specific as follows: the dry medicine raw material getting ingredients in prescription, crude drug is added to the water except Herba Houttuyniae, 2-3cm in the water that submerges, soaks half an hour, decoct 1-2h, filtering residue and Herba Houttuyniae add the water of 3 times of weight again, decoct 20min, merging filtrate, being concentrated into 60 DEG C of relative densities is 1.12-1.18, obtains concentrated solution for subsequent use.Those skilled in the art can add adjuvant conventional formulation technique on this basis can obtain various dosage forms conventional clinically.In order to facilitate patient to use pharmaceutical composition of the present invention better, pharmaceutical composition of the present invention conveniently technique can be prepared into external preparation conventional clinically, as lotion, liniment, tincture, unguentum etc.It is further preferred that pharmaceutical composition of the present invention conveniently preparation technology be prepared into unguentum.
The present invention also asks to protect aforementioned pharmaceutical compositions in the purposes of preparation treatment decubital ulcer particularly in preparation treatment qi stagnation and blood stasis type decubital ulcer medicine.Select clinical case to observe in 76 known treated routine qi stagnation and blood stasis type patients with bedsore, pharmaceutical composition of the present invention has given full play to the drug effect of vital energy regualting and blood circulation-promoting, is beneficial to growth and the wound healing of granulation tissue, has the effect accelerating wound healing.Result shows, pharmaceutical composition of the present invention is evident in efficacy to qi stagnation and blood stasis type decubital ulcer, after medication 3-4 days, skin ulcer face transfers to ruddy by black, dark brown, slough obviously reduces, redness alleviates, slough comes off quickening, add the confession of wound surface blood, improve wound surface microcirculation, facilitate the growth of granulation tissue.After liniment is combined with wound surface, forms protective barrier, decrease infection chance, be conducive to wound healing.The total effective rate 97.37% for the treatment of group of the present invention is far above matched group 76.32%, and pharmaceutical composition of the present invention has extremely significant curative effect to treatment qi stagnation and blood stasis type patients with bedsore, and no case was recurrence, treatments period has no adverse reaction to follow up a case by regular visits to 1 year.Reach the object of vital energy regualting and blood circulation-promoting after thus pharmaceutical composition prescription of the present invention being described, serve the remarkable result that treatment decubital ulcer particularly treats qi stagnation and blood stasis type decubital ulcer.So pharmaceutical composition of the present invention is a kind of external used medicine can extensively promoted for decubital ulcer.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
Embodiment 1
The each raw material of the present invention is taken: the Rhizoma Pinelliae 5 parts, Lasiosphaera Seu Calvatia 2 parts, Radix Sanguisorbae 10 parts, Olibanum 1.2 parts, Rhizoma Polygonati 10 parts, Rhizoma Coptidis 6 parts, the Radix Paeoniae Alba 2 parts, Turpinia pomifera(Roxb) D O. 18 parts, Herba Houttuyniae 10 parts, the Radix Angelicae Dahuricae 15 parts, Fructus Corni 10 parts, the Flos Sophorae Immaturus 20 parts by following weight portion.
Embodiment 2
The each raw material of the present invention is taken: the Rhizoma Pinelliae 20 parts, Lasiosphaera Seu Calvatia 9 parts, Radix Sanguisorbae 18 parts, Olibanum 1.8 parts, Rhizoma Polygonati 20 parts, Rhizoma Coptidis 18 parts, the Radix Paeoniae Alba 8 parts, Turpinia pomifera(Roxb) D O. 30 parts, Herba Houttuyniae 18 parts, the Radix Angelicae Dahuricae 25 parts, Fructus Corni 20 parts, the Flos Sophorae Immaturus 26 parts by following weight portion.
Embodiment 3
The each raw material of the present invention is taken: the Rhizoma Pinelliae 20 parts, Lasiosphaera Seu Calvatia 2 parts, Radix Sanguisorbae 18 parts, Olibanum 1.2 parts, Rhizoma Polygonati 20 parts, Rhizoma Coptidis 6 parts, the Radix Paeoniae Alba 8 parts, Turpinia pomifera(Roxb) D O. 18 parts, Herba Houttuyniae 18 parts, the Radix Angelicae Dahuricae 15 parts, Fructus Corni 20 parts, the Flos Sophorae Immaturus 20 parts by following weight portion.
Embodiment 4
The each raw material of the present invention is taken: the Rhizoma Pinelliae 5 parts, Lasiosphaera Seu Calvatia 9 parts, Radix Sanguisorbae 10 parts, Olibanum 1.8 parts, Rhizoma Polygonati 10 parts, Rhizoma Coptidis 18 parts, the Radix Paeoniae Alba 2 parts, Turpinia pomifera(Roxb) D O. 30 parts, Herba Houttuyniae 10 parts, the Radix Angelicae Dahuricae 25 parts, Fructus Corni 10 parts, the Flos Sophorae Immaturus 26 parts by following weight portion.
Embodiment 5
The each raw material of the present invention is taken: the Rhizoma Pinelliae 13 parts, Lasiosphaera Seu Calvatia 5 parts, Radix Sanguisorbae 14 parts, Olibanum 1.5 parts, Rhizoma Polygonati 15 parts, Rhizoma Coptidis 12 parts, the Radix Paeoniae Alba 5 parts, Turpinia pomifera(Roxb) D O. 24 parts, Herba Houttuyniae 14 parts, the Radix Angelicae Dahuricae 20 parts, Fructus Corni 15 parts, the Flos Sophorae Immaturus 23 parts by following weight portion.
Preparation technology: the dry medicine raw material getting ingredients in prescription, crude drug is added to the water except Herba Houttuyniae, submerge 2-3cm in water, soak half an hour, decoct 1-2h, filtering residue and Herba Houttuyniae add the water of 3 times of weight again, decoct 20min, merging filtrate, being concentrated into 60 DEG C of relative densities is 1.12-1.18, obtains concentrated solution for subsequent use.Those skilled in the art can add adjuvant conventional formulation technique on this basis and obtain the conventional external preparation such as lotion, liniment, tincture, unguentum.
The clinical data of embodiment 6 medicine composite for curing decubital ulcer of the present invention
76 routine patients are divided into treatment group and matched group by random digits table by 1, case-data: selected by this object of study 76 routine patients are diagnosed as qi stagnation and blood stasis type patients with bedsore from hospital's Dermatology and outpatient service, often organize each 38 examples.Wherein paralytic 13 example, because of paralytic patient 19 example that wound causes, patients of acute myocardial infarction 15 example, patients with cor pulmonale 15 example, fracture patient 14 example, at 55 ~ 85 years old age, the course of disease is 10 ~ 50 days, is on average 32.25 days.In treatment group, male 18 example, women 20 example, 56 years old minimum age, 85 years old maximum age, average (70.19 ± 5.60) year, wound surface has 41 places, wherein sacrococcygeal region 29 place, back 6 place, elbow joint 3 place, heel portion 3 place, decubital ulcer area 0.5cm × 0.5cm ~ 6cm × 8cm.In matched group, male 19 example, women 19 example, 55 years old minimum age, 83 years old maximum age, average (71.20 ± 5.65) year, wound surface has 41 places, wherein sacrococcygeal region 30 place, back 6 place, elbow joint 5 place, decubital ulcer area 1cm × 0.5cm ~ 7cm × 7cm.
Two groups of data selected by this are compared, and no matter sex, age, by stages typing, affected part number, decubital ulcer area etc. are through the statistical test difference that there are no significant, and (P>0.05), has comparability.
2, diagnosis basis
1) diagnostic criteria
In People's Republic of China's traditional Chinese medicine industry standard " Chinese medical disease Standardization of diagnosis and curative effect ", the diagnostic criteria of decubital ulcer is as follows:
(1) be apt to occur in the apophysis such as tail sacrum, ridge, elbow ankle easily to suffer oppression and the position that rubs;
(2) from the beginning of skin occurring brown erythema, micro-swollen, purple dark edema then, necrosis is festered;
(3) during secondary contamination, tissue necrosis is rapid, and pus is dripping, corresponding site Bing Fa Xing core pain;
(4) patient of the prolonged illness beds such as stupor, paralysis, fracture, large-area burns is more common in.
2) inclusive criteria
(1) degree of depth of decubital ulcer does not damage sclerotin and joint;
(2) vital sign is steady;
(3) informed consent, patient and family members are ready partner treatment;
(4) enough nutritional supports are had;
(5) without psychology, mental sickness;
(6) during selected and random packet, clinical symptoms is stablized.
3) exclusion standard
(1) sensory disturbance, stupor, hemorrhagic apoplexy (acute stage), diabetes (except glucostasis person);
(2) severe malnutrition, can not oral feeding and refuse other approach extra-nutritions person;
(3) estimate to survive to the critical patient of off-test;
(4) patient and family members refuse partner treatment decubital ulcer person;
(5) allergic constitution, or known to this medicine composition allergy sufferers;
(6) law or spiritual disabled patient;
(7) chronic wounds that causes of other diseases;
(8) various disease whole latter stage, refusal treatment primary disease person;
(9) patient of other drug clinical trial is being participated in.
4) to reject and the standard that comes off
(1) include case selected by rear discovery in and do not meet inclusive criteria;
(2) case is included at duration of test because of certain reason and the person that should not continue reception test;
(3) the not not congruent judgement person that affects the treatment of medication treatment or data according to the rules;
(4) experimenter's compliance is poor, can not complete experimenter on request;
(5) bolter voluntarily in process of the test;
(6) other can not complete experimenter on request, as in process of the test, occur the other reasons Died Patients irrelevant with decubital ulcer.
3, usage and dosage:
Unguentum prepared by treatment group Example 5.Every gram of unguentum, containing crude drug amount 1g, is got 1-2g ointment according to affected part area at every turn and is smeared affected part, three times on the one.
Matched group adopts western medicine routine treatment method, first wound surface is cleaned with normal saline, remove vesicle, ulcer and a large amount of slough, infra-red light irradiation 30min is used after wound surface cleaning, clean again, soak gentamycin wets sliver (0.9% sodium chloride injection 100mL adds gentamycin 240,000 unit) after wound surface of sterilizing, cover with aseptic dressing and wrap up, every day changes dressings 1-2 time, until healing.
Observation of curative effect is carried out after 15 days.
4, efficacy evaluation:
(1) cure: brown erythema disappears, or the wound healing that festers;
(2) take a turn for the better: erythema does not disappear entirely, or the skin ulcer face slough that festers comes off, granulation, and skin ulcer face reduces gradually;
(3) do not heal: the open sore part increases, fester more than.
Total effective rate=(clinical cure number of cases+improvement number of cases)/this organizes total number of cases × 100%.
5, therapeutic effect: in this clinical observation case 76 people, without coming off case, after treatment terminates, the concrete outcome of two groups is in Table.
| ? | Cure | Take a turn for the better | Do not heal | Effective percentage (%) |
| Treatment group | 28 | 9 | 1 | 97.37％％ |
| Matched group | 14 | 15 | 9 | 76.32％ |
Pharmaceutical composition of the present invention has given full play to the drug effect of vital energy regualting and blood circulation-promoting, is beneficial to growth and the wound healing of granulation tissue, has the effect accelerating wound healing.Result shows, pharmaceutical composition of the present invention is evident in efficacy to qi stagnation and blood stasis type decubital ulcer, after medication 3-4 days, skin ulcer face transfers to ruddy by black, dark brown, slough obviously reduces, redness alleviates, slough comes off quickening, add the confession of wound surface blood, improve wound surface microcirculation, facilitate the growth of granulation tissue.After liniment is combined with wound surface, forms protective barrier, decrease infection chance, be conducive to wound healing.So pharmaceutical composition of the present invention is a kind of external used medicine can extensively promoted for decubital ulcer, clinical effectiveness is remarkable.
Claims (7)
1. treat a pharmaceutical composition for decubital ulcer, it is characterized in that, it is obtained by following raw material: the Rhizoma Pinelliae, Lasiosphaera Seu Calvatia, Radix Sanguisorbae, Olibanum, Rhizoma Polygonati, Rhizoma Coptidis, the Radix Paeoniae Alba, Turpinia pomifera(Roxb) D O., Herba Houttuyniae, the Radix Angelicae Dahuricae, Fructus Corni, the Flos Sophorae Immaturus.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, it is obtained by the raw material of following weight portion: Rhizoma Pinelliae 5-20 part, Lasiosphaera Seu Calvatia 2-9 part, Radix Sanguisorbae 10-18 part, Olibanum 1.2-1.8 part, Rhizoma Polygonati 10-20 part, Rhizoma Coptidis 6-18 part, Radix Paeoniae Alba 2-8 part, Turpinia pomifera(Roxb) D O. 18-30 part, Herba Houttuyniae 10-18 part, Radix Angelicae Dahuricae 15-25 part, Fructus Corni 10-20 part, Flos Sophorae Immaturus 20-26 part.
3. pharmaceutical composition as claimed in claim 2, it is characterized in that, it is obtained by the raw material of following weight portion: the Rhizoma Pinelliae 13 parts, Lasiosphaera Seu Calvatia 5 parts, Radix Sanguisorbae 14 parts, Olibanum 1.5 parts, Rhizoma Polygonati 15 parts, Rhizoma Coptidis 12 parts, the Radix Paeoniae Alba 5 parts, Turpinia pomifera(Roxb) D O. 24 parts, Herba Houttuyniae 14 parts, the Radix Angelicae Dahuricae 20 parts, Fructus Corni 15 parts, the Flos Sophorae Immaturus 23 parts.
4. the pharmaceutical composition as described in claim 1-3, is characterized in that, described pharmaceutical composition is external preparation.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, described external preparation is lotion, liniment, tincture, unguentum.
6. pharmaceutical composition as claimed in claim 5, it is characterized in that, described external preparation is unguentum.
7. the purposes of the pharmaceutical composition as described in claim 1-6 in preparation treatment qi stagnation and blood stasis type decubital ulcer medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410652385.XA CN104306707A (en) | 2014-11-16 | 2014-11-16 | Medicament composition for treating bedsore |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410652385.XA CN104306707A (en) | 2014-11-16 | 2014-11-16 | Medicament composition for treating bedsore |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104306707A true CN104306707A (en) | 2015-01-28 |
Family
ID=52362116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410652385.XA Pending CN104306707A (en) | 2014-11-16 | 2014-11-16 | Medicament composition for treating bedsore |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104306707A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758858A (en) * | 2015-04-29 | 2015-07-08 | 赵振荣 | Medicine for treating Qi-stagnancy and blood stasis bedsore and preparation method thereof |
| CN105168386A (en) * | 2015-08-27 | 2015-12-23 | 陈红 | Traditional Chinese medicine composition for treating qi-stagnation and blood-stasis type bedsore and preparation method of traditional Chinese medicine composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814198A (en) * | 2005-11-18 | 2006-08-09 | 杨丽 | Medicine for preventing bedsore resulted from Qi-stagnation and blood-stagnation, and preparing method |
| CN102091203A (en) * | 2011-01-19 | 2011-06-15 | 李惠斌 | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof |
| CN102125634A (en) * | 2011-02-25 | 2011-07-20 | 曹广玲 | Chinese medicinal composition for treating bedsore |
-
2014
- 2014-11-16 CN CN201410652385.XA patent/CN104306707A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1814198A (en) * | 2005-11-18 | 2006-08-09 | 杨丽 | Medicine for preventing bedsore resulted from Qi-stagnation and blood-stagnation, and preparing method |
| CN102091203A (en) * | 2011-01-19 | 2011-06-15 | 李惠斌 | External traditional Chinese medicine preparation for treating chronic wounds and preparation method thereof |
| CN102125634A (en) * | 2011-02-25 | 2011-07-20 | 曹广玲 | Chinese medicinal composition for treating bedsore |
Non-Patent Citations (3)
| Title |
|---|
| 封志英: "褥疮的中医药治疗近况", 《护理研究》 * |
| 张宇慈等: "中药白芷外敷治疗褥疮14例", 《吉林中医药》 * |
| 高京华等: "马勃治疗褥疮的疗效对照观察", 《现代中医药》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758858A (en) * | 2015-04-29 | 2015-07-08 | 赵振荣 | Medicine for treating Qi-stagnancy and blood stasis bedsore and preparation method thereof |
| CN105168386A (en) * | 2015-08-27 | 2015-12-23 | 陈红 | Traditional Chinese medicine composition for treating qi-stagnation and blood-stasis type bedsore and preparation method of traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105833279B (en) | External-use medicine composition for treating various wound surfaces of skin and preparation method thereof | |
| CN102091203B (en) | External traditional Chinese medicine preparation for treating refractory wound and preparation method thereof | |
| CN103893458B (en) | Diabetic foot ulcer external medicine composition, preparation method and applications | |
| CN103893557A (en) | Traditional Chinese medicine preparation for treating bedsore | |
| CN104306707A (en) | Medicament composition for treating bedsore | |
| CN105902660A (en) | Pharmaceutical composition for treating bedsores, diabetic feet and eczema | |
| CN109045204A (en) | A kind of herb liquid and preparation method thereof for treating burn and scald | |
| CN105250712B (en) | A kind of Chinese medicine composition for treating bedsore | |
| CN104983932B (en) | newborn red hip lotion | |
| CN113041301A (en) | Multifunctional burn ointment and preparation method thereof | |
| CN105560687A (en) | Traditional Chinese medicine compound external coating liquid for treating skin ulcers and preparation method and application thereof | |
| CN105250685A (en) | Traditional Chinese medicine composition for treating burns and preparation method of traditional Chinese medicine composition | |
| CN104306734B (en) | Treat diabetic gangrene externally applied ointment preparation and preparation method thereof | |
| CN104623304A (en) | Lotion for treating chronic skin ulcer caused by damp-heat and toxicity accumulation and preparation method of lotion | |
| CN116531460B (en) | Traditional Chinese medicine powder for treating huge bedsores and preparation method thereof | |
| CN112439008A (en) | Medical application of Yinzhihuang preparation | |
| CN116585404B (en) | External traditional Chinese medicine composition for treating adult simple skin pruritus and preparation method thereof | |
| CN110403995B (en) | Traditional Chinese medicine composition for treating superficial phlebitis and preparation, use methods and application thereof | |
| CN108066466A (en) | A kind of Chinese medicine composition for treating burn and scald and preparation method and application | |
| CN101607069B (en) | Chinese traditional medicine for treating phlebitis, old lower extremity venous ulcer and venous purpura disease | |
| CN107137649A (en) | A kind of instant particles as Chinese medicine and preparation method for treating Female Urethral Syndrome | |
| CN105832909A (en) | Traditional Chinese medicine preparation for treating necrotic ulcer of skin | |
| CN106511825A (en) | Traditional Chinese medicine for bedsore nursing | |
| CN105362516A (en) | Tincture for treating plasmacellular mastitis and preparation method thereof | |
| WO2025065255A1 (en) | Burn and scald tincture and preparation method therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150128 |
|
| RJ01 | Rejection of invention patent application after publication |